The U.S. Food and Drug Administration (FDA) has officially approved Johnson & Johnson’s nasal spray, Spravato, as a standalone treatment for depression. This decision marks a significant advancement in the management of major depressive disorder, particularly for patients who have not responded to traditional therapies. The approval is based on clinical trials demonstrating the efficacy and safety of the treatment, which offers a new option for individuals struggling with this debilitating condition.
Tag: Johnson & Johnson
FDA Grants Approval for Johnson & Johnson’s Nasal Spray as a Standalone Treatment for Depression
The U.S. Food and Drug Administration (FDA) has officially approved Johnson & Johnson’s nasal spray, Spravato, as a standalone treatment for depression. This decision marks a significant advancement in the management of major depressive disorder, particularly for patients who have not responded to traditional therapies. The approval is based on clinical trials demonstrating the spray’s efficacy and safety, providing a new option for those struggling with this debilitating condition.